Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Artiva Biotherapeutics (ARTV) Total Current Liabilities (2023 - 2025)

Artiva Biotherapeutics (ARTV) has disclosed Total Current Liabilities for 3 consecutive years, with $13.1 million as the latest value for Q4 2025.

  • Quarterly Total Current Liabilities rose 6.81% to $13.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $13.1 million through Dec 2025, up 6.81% year-over-year, with the annual reading at $13.1 million for FY2025, 6.81% up from the prior year.
  • Total Current Liabilities for Q4 2025 was $13.1 million at Artiva Biotherapeutics, up from $11.1 million in the prior quarter.
  • The five-year high for Total Current Liabilities was $13.3 million in Q3 2024, with the low at $10.8 million in Q2 2025.
  • Average Total Current Liabilities over 3 years is $12.0 million, with a median of $12.2 million recorded in 2023.
  • Peak annual rise in Total Current Liabilities hit 6.81% in 2025, while the deepest fall reached 16.35% in 2025.
  • Over 3 years, Total Current Liabilities stood at $12.2 million in 2023, then rose by 0.21% to $12.3 million in 2024, then increased by 6.81% to $13.1 million in 2025.
  • According to Business Quant data, Total Current Liabilities over the past three periods came in at $13.1 million, $11.1 million, and $10.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.